Summary
Protein phosphorylation plays key roles in many physiological processes and is often deregulated in pathological conditions. Our current understanding of how protein kinases and phosphatases orchestrate the phosphorylation changes that control cellular functions has made these enzymes potential drug targets for the treatment of many diseases. The success of the tyrosine kinase inhibitor Gleevec in the treatment of some cancer has further invigorated the development of kinase inhibitors as anti-cancer drugs. A larger number of these compounds are currently undergoing clinical trials and there is much expectation on the therapeutic potential of these molecules, as more specific and less toxic drugs than currently used generic chemotherapeutic agents. In this manuscript, we review the current status of more than 30 protein kinase inhibitors with proven or potential therapeutic value for cancer treatment. These include inhibitors of receptor and cytosolic tyrosine kinases as well as compounds that target different families of serine/threonine kinases involved in signalling and cell cycle regulation. We also briefly touch on the prospects of phosphatase inhibitors. The combination of kinase inhibitors to target different components of signalling pathways that are found deregulated in tumours is also emerging as an interesting approach for cancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Manning G, Whyte DB, Martínez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.
Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296–313.
Cohen P: Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:509–15.
Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004; 303:1800–5.
Biondi RM, Nebrada AR. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J. 2003;372:1–13.
Ducruet AP, Vogt A, Wipf P, Lazo JS. Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2005; 45:725–50.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;355:172–87.
Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol. 2003;7:490–5.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;105:211–25.
Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-AbI tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5:33–44.
Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;505:1163–7.
Watanabe D, Ezoe S, Fujimoto M, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004;126:726–35.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;544:785–92.
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344;1038–42.
Martinelli G, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005;19:1872–9.
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;505:399–401.
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;547:472–80.
Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30:630–41.
Malumbres M, Barbacid M. Is Cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell. 2006;9:2–4.
Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5:566–73.
Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–9.
Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mototic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8: 7–12.
Eckerdt F, Yuan, J, Strebhardt K. Polo-like kinase and oncogenesis. Oncogene. 2005; 24:267–76.
Giet R, Petretti C., Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. 2005;15: 241–50.
Gumiredy K, Reddy MV, Consenza SC, et al. ONO 1910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7:275–86.
Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene. 2005;24:5005–15.
Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927–36.
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.
Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005;24:7482–92.
Kumar CC, Madison V: AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005;24:7493–501.
Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle. 2005;4:1540–9.
Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin Oncol. 2004; 51:10–7; discussion 33.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463–9.
Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005; 23:6771–90.
Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4:937–47.
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;459:558–62.
Bulavin DV, Fornace AJ, Jr.. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95–118.
Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004;10:125–9.
Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov. 2003;2:554–65.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117:699–711.
Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem. Biol. 2004;11: 1043–51.
Gallego M, Virshup DM. Protein serine/threonine phosphatases: life, death, and sleeping. Curr Opin Cell Biol. 2005;17: 197–202.
Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor supressor pathway. J Clin Oncol. 2004;22: 2954–65.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supported by an unrestricted educational grant from Pfizer.
Rights and permissions
About this article
Cite this article
Ventura, JJ., Nebreda, Á.R. Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 8, 153–160 (2006). https://doi.org/10.1007/s12094-006-0005-0
Issue Date:
DOI: https://doi.org/10.1007/s12094-006-0005-0